A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

• ClinicalTrials.gov Identifier: NCT01484561
• Recruitment Status: Completed
• First Posted: December 2, 2011
• Results First Posted: April 2, 2014
• Last Update Posted: April 2, 2014
• Sponsor: Pfizer
• Information provided by (Responsible Party): Pfizer

Study Description

Brief Summary:

The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).

Condition or disease	Intervention/treatment	Phase
Arthritis, Rheumatoid	Drug: CP-690,550 or Placebo; Drug: Placebo	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 148 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Basic Science
• Official Title: A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis
• Study Start Date: April 2012
• Actual Primary Completion Date: January 2013
• Actual Study Completion Date: February 2013

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Sequence 1	Drug: CP-690,550 or Placebo; CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
Placebo Comparator: Sequence 2	Drug: Placebo; Placebo BID orally, approximately 72 days

Outcome Measures

Primary Outcome Measures :

1. Adjusted Geometric (Geo) Mean-Fold Change at End of Period 1 From Baseline in Measured Glomerular Filtration Rate (mGFR) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
   Glomerular filtration rate (GFR) is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. mGFR was determined using iohexol serum clearance using compartmental modeling of the iohexol serum concentration-time data. mGFR values were normalized to 1.73 meters squared (m^2) body surface area. A normal GFR is greater than (>)90 milliliters per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR <15 mL/min is consistent with kidney failure. Baseline was defined as the mean of the values obtained at Run-in and on predose in Period 1/Day 1.

Secondary Outcome Measures :

1. Adjusted Geometric Mean-Fold Change at the End of Period 2 From Baseline in mGFR [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
   mGFR was determined using iohexol serum clearance using compartmental modeling of the iohexol serum concentration-time data. mGFR values were normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Run-in and on predose in Period 1/Day 1.
2. Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in mGFR [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
   mGFR was determined using iohexol serum clearance using compartmental modeling of the iohexol serum concentration-time data. mGFR values were normalized to 1.73 m^2 body surface area.
3. Adjusted Geometric Mean-Fold Change at End of Period 1 From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using Modified Diet in Renal Disease (MDRD) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
   eGFR was calculated using the MDRD equation and normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.
4. Adjusted Geometric Mean-Fold Change at End of Period 2 From Baseline in eGFR Using MDRD [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
   eGFR was calculated using the MDRD equation with eGFR values normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.
5. Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in eGFR Using MDRD [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
   eGFR was calculated using the MDRD equation with eGFR values normalized to 1.73 m^2 body surface area.
6. Adjusted Geometric Mean-Fold Change at End of Period 1 From Baseline in eGFR Using the Cockcroft-Gault Equation [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
   eGFR was calculated using the Cockcroft-Gault equation normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.
7. Adjusted Geometric Mean-Fold Change at End of Period 2 From Baseline in eGFR Using the Cockcroft-Gault Equation [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
   eGFR was calculated using the Cockcroft-Gault equation normalized to 1.73 m^2 body surface area. Baseline was defined as the mean of the values obtained at Screening and on predose in Period 1/Day 1.
8. Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in eGFR Using the Cockcroft-Gault Equation [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
   eGFR was calculated using the Cockcroft-Gault equation normalized to 1.73 m^2 body surface area.
9. Adjusted Geometric Mean-Fold Change at End of Period 1 From Baseline in Serum Creatinine [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
   Blood samples were collected from participants at screening, predose on Day 1 of Period 1, on the last day of Period 1 and on the last day of Period 2 for assessment of serum creatinine levels. Serum creatinine values in milligrams per deciliter (mg/dL) reported by the central laboratory were used. Baseline for serum creatinine was defined as the mean of values obtained at screening and predose on Day 1 of Period 1.
10. Adjusted Geometric Mean-Fold Change From End of Period 2 From Baseline in Serum Creatinine [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    Blood samples were collected from participants at screening, predose on Day 1 of Period 1, on the last day of Period 1 and on the last day of Period 2 for assessment of serum creatinine levels. Serum creatinine values in mg/dL reported by the central laboratory were used. Baseline for serum creatinine was defined as the mean of values obtained at screening and predose on Day 1 of Period 1.
11. Adjusted Geometric Mean-Fold Change at End of Period 2 From End of Period 1 in Serum Creatinine [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
    Blood samples were collected from participants at screening, predose on Day 1 of Period 1, on the last day of Period 1 and on the last day of Period 2 for assessment of serum creatinine levels. Serum creatinine values in mg/dL reported by the central laboratory were used.
12. Percentage of Participants Achieving an American College of Rheumatology 20% (ACR20) Response [ Time Frame: Day 1 of Period 1 to Day 43 of Period 1, Day 1 of Period 1 to Day 29 of Period 2 ]
    ACR20 response: greater than or equal to (≥)20 percent (%) improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
13. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response [ Time Frame: Day 1 of Period 1 to Day 43 of Period 1, Day 1 of Period 1 to Day 29 of Period 2 ]
    ACR50 response: ≥50% improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a HAQ, and 5) CRP at each visit.
14. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response [ Time Frame: Day 1 of Period 1 to Day 43 of Period 1, Day 1 of Period 1 to Day 29 of Period 2 ]
    ACR70 response: ≥70% improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant' assessment of functional disability via a HAQ, and 5) CRP at each visit.
15. Least Squares (LS) Mean Change at End of Period 1 From Baseline in Disease Activity Score Based on 28-Joint Count CRP (DAS28-3 [CRP]) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    DAS28 calculated from the tender/painful joint count, swollen joint count (SJC) using the 28 joints count, and CRP value. DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (>)3.2 to 5.1 = moderate to high disease activity.
16. LS Mean Change at End of Period 2 From Baseline in DAS28-3 (CRP) [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    DAS28 calculated from the tender/painful joint count, SJC using the 28 joints count, and CRP value. DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
17. LS Mean Change at End of Period 2 From End of Period 1 in DAS28-3 (CRP) [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
    DAS28 calculated from the tender/painful joint count, SJC using the 28 joints count, and CRP value. DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
18. LS Mean Change at End of Period 1 From Baseline DAS28-4 (CRP) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    DAS28 calculated from the number of SJC and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
19. LS Mean Change at End of Period 2 From Baseline DAS28-4 (CRP) [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    DAS28 calculated from the number of SJC and PJC using the 28 joints count, the ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
20. LS Mean Change at End of Period 2 From End of Period 1 DAS28-4 (CRP) [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
    DAS28 calculated from the number of SJC and PJC using the 28 joints count, the ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
21. LS Mean Change at End of Period 1 From Baseline in Tender/Painful Joint Count [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    68 joints were assessed by a joint assessor to determine the number of joints that were considered tender or painful Assessed joints included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb interphalangeal [IP], PIP, and distal interphalangeals [DIP]), and lower extremity (hip, knee, ankle, tarsus, metatarsophalangeals [MTP], great toe IP, proximal and distal interphalangeals combined [PIP]).
22. LS Mean Change at End of Period 2 From Baseline in Tender/Painful Joint Count [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    68 joints were assessed by a joint assessor to determine the number of joints that were considered tender or painful Assessed joints included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (hip, knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).
23. LS Mean Change at End of Period 2 From End of Period 1 in Tender/Painful Joint Count [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
    68 joints were assessed by a joint assessor to determine the number of joints that were considered tender or painful Assessed joints included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (hip, knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).
24. LS Mean Change at End of Period 1 From Baseline in Swollen Joint Count [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    Swollen joint count included 66 joints. Assessor assessed joints for swelling using the following scale: present/absent/not done/not applicable (to be used for artificial joints). Joints assessed included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).
25. LS Mean Change at End of Period 2 From Baseline in Swollen Joint Count [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    Swollen joint count included 66 joints. Assessor assessed joints for swelling using the following scale: present/absent/not done/not applicable (to be used for artificial joints). Joints assessed included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).
26. LS Mean Change at End of Period 2 From End of Period 1 in Swollen Joint Count [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
    Swollen joint count included 66 joints. Assessor assessed joints for swelling using the following scale: present/absent/not done/not applicable (to be used for artificial joints). Joints assessed included: upper body (temporomandibular, sternoclavicular, acromioclavicular), upper extremity (shoulder, elbow, wrist, MCP, thumb IP, PIP, and DIP), and lower extremity (knee, ankle, tarsus, MTP, great toe IP, proximal and distal interphalangeals combined [PIP]).
27. LS Mean Change at End of Period 1 From Baseline in CRP [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
28. LS Mean Change at End of Period 2 From Baseline in CRP [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
29. LS Mean Change at End of Period 2 From End of Period 1 in CRP [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
30. LS Mean Change at End of Period 1 From Baseline in Patient Global Assessment of Arthritis (PGAA) [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 millimeter (mm) visual analog scale (VAS), where 0 mm = very well and 100 mm = very poorly.
31. LS Mean Change at End of Period 2 From Baseline in PGAA [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participants responses were recorded using a 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
32. LS Mean Change at End of Period 2 From End of Period 1 in PGAA [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
    Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participants responses were recorded using a 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
33. LS Mean Change at End of Period 1 From Baseline in Physician Global Assessment of Arthritis [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    A physician assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination. The physician's response was recorded using a 100 mm VAS, where 0 mm = very good and 100 mm = very poor.
34. LS Mean Change at End of Period 2 From Baseline in Physician Global Assessment of Arthritis [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    A physician assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination. The physician's response was recorded using a 100 mm VAS, where 0 mm = very good and 100 mm = very poor.
35. LS Mean Change at End of Period 2 From End of Period 1 in Physician Global Assessment of Arthritis [ Time Frame: Day 43 of Period 1, Day 29 of Period 1 ]
    A physician assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination. The physician's response was recorded using a 100 mm VAS, where 0 mm = very good and 100 mm = very poor.
36. LS Mean Change at End of Period 1 From Baseline in Patient Assessment of Arthritis Pain [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    Participant's assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.
37. LS Mean Change at End of Period 2 From Baseline in Patient Assessment of Arthritis Pain [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    Participant's assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.
38. LS Mean Change at End of Period 2 From End of Period 1 in Patient Assessment of Arthritis Pain [ Time Frame: Day 43 of Period 2, Day 29 of Period 2 ]
    Participant's assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.
39. LS Mean Change at End of Period 1 From Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) Score [ Time Frame: Day 1 of Period 1, Day 43 of Period 1 ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
40. LS Mean Change at End of Period 2 From Baseline HAQ-DI Score [ Time Frame: Day 1 of Period 1, Day 29 of Period 2 ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
41. LS Mean Change at End of Period 2 From End of Period 1 HAQ-DI Score [ Time Frame: Day 43 of Period 1, Day 29 of Period 2 ]
    HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• The patient must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the seven criteria.
• The patient must have active disease at both Screening and predose on Day 1 of Period 1.
• Patient must have had an inadequate response to at least one disease-modifying antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or intolerance.

Exclusion Criteria:

• Pregnant or lactating women
• Serious medical conditions that would make treatment with CP-690,550 potentially unsafe.
• A patient who has a history of asthma, multiple allergies or severe allergy (eg, anaphylaxis) to any substance. In particular, a history of allergy to iodine, povidone-iodine, iohexol or other iodinated contrast media.

Contacts and Locations

Locations

United States, Florida

Pfizer Investigational Site

South Miami, Florida, United States, 33143

United States, New York

Pfizer Investigational Site

Albany, New York, United States, 12206

United States, Pennsylvania

Pfizer Investigational Site

Duncansville, Pennsylvania, United States, 16635

United States, Texas

Pfizer Investigational Site

Dallas, Texas, United States, 75231

United States, Washington

Pfizer Investigational Site

Tacoma, Washington, United States, 98405

Czech Republic

Pfizer Investigational Site

Praha 4, Czech Republic, 140 59

Germany

Pfizer Investigational Site

Berlin, Germany, 13125

Pfizer Investigational Site

Erlangen, Germany, 91054

Pfizer Investigational Site

Wuerzburg, Germany, 97080

Korea, Republic of

Pfizer Investigational Site

Seoul, Korea, Republic of, 120-752

Mexico

Pfizer Investigational Site

Merida, Yucatan, Mexico, 97000

Poland

Pfizer Investigational Site

Bialystok, Poland, 15-354

Pfizer Investigational Site

Bydgoszcz, Poland, 85-168

Pfizer Investigational Site

Warszawa, Poland, 01-192

Pfizer Investigational Site

Warszawa, Poland, 02-256

Pfizer Investigational Site

Wroclaw, Poland, 50-088

Russian Federation

Pfizer Investigational Site

Moscow, Russian Federation, 115522

Pfizer Investigational Site

Petrozavodsk, Russian Federation, 185019

Pfizer Investigational Site

Saint Petersburg, Russian Federation, 197341

Pfizer Investigational Site

St. Petersburg, Russian Federation, 194291

Spain

Pfizer Investigational Site

Barakaldo, Vizcaya, Spain, 48903

Pfizer Investigational Site

Bilbao, Vizcaya, Spain, 48013

Pfizer Investigational Site

La Coruna, Spain, 15006

Pfizer Investigational Site

Sevilla, Spain, 41009

Sponsors and Collaborators

Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.

Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2020 Oct 10;:

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.

Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, Vlahos B, Hammond C, Bukowski J, Li H, Schulman SL, Raber S, Zuckerman A, Isaacs JD. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Res Ther. 2015 Apr 6;17(1):95. doi: 10.1186/s13075-015-0612-7.

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT01484561
• Other Study ID Numbers: A3921152
• First Posted: December 2, 2011
• Results First Posted: April 2, 2014
• Last Update Posted: April 2, 2014
• Last Verified: March 2014

Keywords provided by Pfizer:

Phase 1

Additional relevant MeSH terms:

Arthritis; Arthritis, Rheumatoid; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Tofacitinib; Janus Kinase Inhibitors; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action